Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
IndexS&P 500 P/E32.81 EPS (ttm)7.40 Insider Own1.60% Shs Outstand96.88M Perf Week-2.46%
Market Cap23.52B Forward P/E39.97 EPS next Y6.07 Insider Trans-23.49% Shs Float77.76M Perf Month-9.07%
Income837.50M PEG1.31 EPS next Q0.92 Inst Own77.90% Short Float4.48% Perf Quarter38.50%
Sales1.59B P/S14.82 EPS this Y375.50% Inst Trans-0.26% Short Ratio3.10 Perf Half Y35.08%
Book/sh14.52 P/B16.72 EPS next Y56.84% ROA44.80% Target Price287.94 Perf Year118.92%
Cash/sh3.18 P/C76.43 EPS next 5Y25.03% ROE82.70% 52W Range107.31 - 283.99 Perf YTD41.91%
Dividend- P/FCF601.49 EPS past 5Y44.00% ROI46.60% 52W High-18.04% Beta0.88
Dividend %- Quick Ratio6.40 Sales past 5Y61.60% Gross Margin93.60% 52W Low116.91% ATR11.04
Employees1996 Current Ratio6.60 Sales Q/Q89.70% Oper. Margin37.10% RSI (14)44.55 Volatility4.89% 4.66%
OptionableYes Debt/Eq0.33 EPS Q/Q718.20% Profit Margin52.80% Rel Volume0.46 Prev Close242.76
ShortableYes LT Debt/Eq0.33 EarningsJul 22 Payout0.00% Avg Volume1.12M Price232.77
Recom2.20 SMA20-5.38% SMA50-3.05% SMA20026.49% Volume422,221 Change-4.12%
17-May-13Initiated UBS Neutral $290
06-May-13Reiterated RBC Capital Mkts Outperform $270 → $286
06-May-13Reiterated Barclays Overweight $275 → $305
02-May-13Reiterated Barclays Overweight $194 → $275
28-Feb-13Initiated Barclays Overweight $194
21-Dec-12Reiterated RBC Capital Mkts Outperform $171 → $190
14-Feb-12Reiterated RBC Capital Mkts Outperform $83 → $130
10-Jan-12Upgrade Robert W. Baird Neutral → Outperform $56 → $81
05-Dec-11Reiterated Brean Murray Buy $78 → $67
28-Jul-11Upgrade RBC Capital Mkts Sector Perform → Outperform $70 → $70
09-May-11Reiterated Needham Buy $49 → $60
29-Apr-11Reiterated Barclays Capital Overweight $64 → $72
29-Apr-11Downgrade RBC Capital Mkts Outperform → Sector Perform $70 → $70
28-Apr-11Reiterated RBC Capital Mkts Outperform $48 → $70
28-Apr-11Reiterated Brean Murray Buy $67 → $78
27-Apr-11Reiterated Brean Murray Buy $57 → $67
27-Apr-11Reiterated Barclays Capital Overweight $61 → $64
27-Apr-11Initiated Boenning & Scattergood Outperform $58
18-Apr-11Reiterated Brean Murray Buy $46 → $57
13-Apr-11Reiterated Barclays Capital Overweight $47 → $56
19-Jun-13 01:03PM  3 Stocks Dragging The Drugs Industry Downward at TheStreet
18-Jun-13 05:17PM  Today's 3 Best Stocks at Motley Fool
04:21PM  Stocks Up Ahead Of Fed; Proto Labs Breaks Out at Investor's Business Daily
12:26PM  Top Treatments for High Cholesterol at Motley Fool
12:25PM  5 Undervalued Stocks Flying Under The Radar! at Forbes
15-Jun-13 01:16PM  Biotechs Lose Ground As Achillion Takes a Dive at Motley Fool
10:56AM  Is This Eye Drug Worth The Hype? at Motley Fool
14-Jun-13 05:01PM  Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Health Care Laggard at TheStreet
10:32AM  Valeant Biting More Than it Can Chew at Motley Fool
13-Jun-13 04:23PM  Stocks Stage Huge Comeback; Myriad Turns Tail at Investor's Business Daily
01:28PM  Stocks Hold Near Highs; MasterCard Firms Up At 10-Week Line at Investor's Business Daily
01:28PM  Stocks Gain, Hold Near Highs: MasterCard Finds Support at Investor's Business Daily
12:30PM  A Growth Investor Who Smartly Balances Blue Chips And Biotech at Forbes
12-Jun-13 02:20PM  Does This Pipeline Promise Tomorrow's Blockbuster Sales? at Motley Fool
01:38PM  Biogen Stock Dips On Concerns Of MS Drug Protection at Investor's Business Daily
11:10AM  The First Real Cure in the $25 billion Asthma Market? at Motley Fool
06:15AM  Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund Zacks
11-Jun-13 03:10PM  Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 08:40 AM at Seeking Alpha
10-Jun-13 03:49PM  Opko: More Hidden Value In Partnerships, Equity Investments at Seeking Alpha
01:03PM  5 Drugs Stocks Dragging The Industry Down at TheStreet
10:09AM  5 Stocks To Watch Closely This Week at Seeking Alpha
10:00AM  Regeneron Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (REGN) at TheStreet
08-Jun-13 05:19AM  [$$] Charting the Market at Barrons.com
07-Jun-13 07:28PM  Many IBD 50 Stocks Show Bullish Action, Find Support at Investor's Business Daily
06:41PM  Many IBD 50 Stocks Show Bullish Action, Find Support at Investor's Business Daily
03:45PM  Positive Data on Bayer/REGN's Eye Drug Zacks
01:31PM  [video] Former Oracle Exec Hired At Salesforce.com at CNBC
12:33PM  Cramer: The Market Welcomes the Jobs Number at TheStreet
08:21AM  Futures Whittle Early Losses; JinkoSolar Spikes On Earnings at Investor's Business Daily
06-Jun-13 06:40PM  4 Healthcare Stock Stories Creating a Thursday Buzz at Wall St. Cheat Sheet +9.81%
05:15PM  Today's 3 Best Stocks at Motley Fool
05:07PM  Stocks End Up After Seesaw Ride; Regeneron Jumps 10% at Investor's Business Daily
05:02PM  Stocks Jump on High Volatility as Investors Await Payrolls Report at TheStreet
05:00PM  Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner at TheStreet
04:49PM  Regeneron shares soar on new testing for eye medicine at MarketWatch
03:52PM  Regeneron Shares Jump As Eye Drug Meets New Study Goal at Barrons.com
03:02PM  Regeneron and Bayer say Eylea meets new study goal AP
11:00AM  OPKO Looks Lucrative As Acquired HGH-CTP Moves Into Phase III Trials at Seeking Alpha
10:49AM  Cramer: Buy Regeneron Pharma, Ventas, National Grid, and This Hot Stock at Wall St. Cheat Sheet
10:38AM  Stocks Rise as Jobless Claims Fall, Europe Keeps Rates Low at TheStreet
05:49AM  Regeneron, Bayer reports positive Phase 3 results for Eylea theflyonthewall.com
02:43AM  Bayer say VEGF Trap-Eye shows promise as mCNV treatment at Reuters
02:30AM  Regeneron and Bayer Report Positive Phase 3 Results for EYLEA® (aflibercept) Injection in Myopic Choroidal Neovascularization (mCNV) PR Newswire
05-Jun-13 04:33PM  Celgene, Biogen Lead IBD 50's Top 5 Biotechs at Investor's Business Daily
11:17AM  Two More Weekly LCD Sell Signals at Forbes
03-Jun-13 09:02PM  Big Cap 20: Celgene, LinkedIn Now Below 10-Week Lines at Investor's Business Daily
06:02PM  Cramer: Out with the New, In with the Old at CNBC
05:00PM  CHMP Positive on Aegerion's Lojuxta Zacks
04:00PM  New drugs trail many old ones in effectiveness against disease at Reuters
09:22AM  Lockheed Martin Executive VP Sells More Than 62K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
01-Jun-13 02:00PM  A $90 Price Target for This Biotech! Hows It Figured? at Motley Fool
31-May-13 01:46PM  Stocks to Buy: Biotechs With Growth Potential at Motley Fool
12:51PM  3 Significant Insider Sells in Healthcare Worth Noting at Motley Fool
01:07AM  German stocks - Factors to watch on May 31 at Reuters
30-May-13 07:00PM  UK cost agency recommends Bayer, Regeneron eye drug at Reuters
05:00PM  Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Winner at TheStreet
01:56PM  Regeneron's Blockbuster Drug Eylea And Its Potential Competitors at Seeking Alpha
11:02AM  Can This Biotech Roar Past $300? at Motley Fool
06:00AM  What's Your Exit Strategy? TheStreet
04:53AM  2 Potentially Explosive Small Cap Stocks For 2013 at Seeking Alpha
29-May-13 04:20PM  Is College Debt a Drag on These Promising Healthcare Stocks at Motley Fool
01:20PM  Regeneron Pharmaceuticals, Inc. Presents at 38th Annual Deutsche Bank Health Care Conference, May-29-2013 08:40 AM at Seeking Alpha
28-May-13 10:00AM  Regeneron Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (REGN) at TheStreet
09:05AM  Clearing The Air On The Sanofi-Regeneron Asthma Drug Trial at Seeking Alpha
26-May-13 09:15AM  The Hidden Danger of Car Exhaust at Motley Fool
25-May-13 11:31AM  Meet the 4 Newest Members of the S&P 500 at Motley Fool
23-May-13 07:06PM  Todays 3 Worst Stocks at Motley Fool
05:01PM  Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard at TheStreet
02:04PM  Agree To Buy Regeneron Pharmaceuticals At $165, Earn 9.8% at Forbes
02:04PM  Amgen Stock Checkup for May at Motley Fool
09:01AM  Applied Materials CEO Sells 300K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
22-May-13 05:22PM  Is This Momentum Stocks Rally Over? at Motley Fool
04:00PM  Sanofi/REGN's Dupilumab Data Published Zacks
03:56PM  Regeneron Shareholders Watching Optina Trial Closely at Seeking Alpha
03:20PM  Regeneron moves higher on asthma drug study data AP
02:06PM  Wednesdays movers: Saks rallies for third day at MarketWatch
12:09PM  Stocks Stage Broad Advance; Bristol-Myers Leads Medicals at Investor's Business Daily
11:51AM  Wednesdays movers: Drug makers lead S&P 500 at MarketWatch
08:05AM  Check Out 5 Big Caps With Long-Term Growth Prospects at Investor's Business Daily
21-May-13 06:32PM  Regeneron and Sanofi: An Unstoppable Biotech Duo? at Motley Fool
04:12PM  New Drug May Help Some Asthmatics, Study Finds at New York Times
08:52AM  New Asthma Drug Generates Excitement For Patients -- And Its Maker at Forbes
08:15AM  InPlay: Regeneron Pharms and Sanofi and announce publication of positive Phase 2a results of dupilumab in asthma in the New England Journal of Medicine Briefing.com
08:15AM  Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine PR Newswire
08:14AM  Regeneron, Sanofi asthma drug seen as potential game changer at Reuters
20-May-13 07:01PM  On The Fly: After Hours Movers at theflyonthewall.com
06:26PM  Regeneron settles all pending litigation with Roche's Genentech at Reuters
01:50PM  Regeneron Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-20-2013 10:00 AM at Seeking Alpha
01:04PM  5 Stocks Underperforming Today In The Drugs Industry at TheStreet
10:07AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
10:01AM  Regeneron Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (REGN) at TheStreet
09:51AM  2 Healthcare Companies And 1 Consumer Goods Company With Recent Intensive Insider Selling at Seeking Alpha
18-May-13 02:30PM  Will ASCO Unlock Big Value in This Cancer Drug Class? at Motley Fool
17-May-13 06:51PM  IBD 50 Stocks Delivering Strong Earnings, Sales Gains at Investor's Business Daily
03:21AM  Coverage initiated on Regeneron Pharms by UBS Briefing.com
16-May-13 03:38PM  A Fundamental, Bottom-Up Approach to Investing in Health Care: Portfolio Manager Finny Kuruvilla Discusses His Strategies with The Wall Street Transcript Wall Street Transcript
09:49AM  Pepper Snapple Group CEO Sells More Than 67K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
09:19AM  S&P 500 Stocks Farthest Above 50-DMAs at Seeking Alpha
08:28AM  Sanofi and Regeneron's Latest Partnership at Motley Fool
07:51AM  The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals Zacks
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aberman Michael SVP Strategy and Investor RelatJun 17Option Exercise24.003,90093,60015,600Jun 18 09:08 AM
BAKER CHARLES ADirectorJun 10Option Exercise15.8015,000237,00024,000Jun 12 09:15 AM
BAKER CHARLES ADirectorJun 10Sale251.8415,0003,777,5479,000Jun 12 09:15 AM
RYAN ARTHUR FDirectorMay 31Sale249.552,500623,88534,855May 31 04:09 PM
GOLDSTEIN JOSEPH LDirectorMay 28Sale252.204,0001,008,8000May 28 04:08 PM
GOLDBERG MURRAY ASVP Finance and Admin CFO andMay 21Option Exercise19.494,02378,396125,389May 22 05:12 PM
GOLDBERG MURRAY ASVP Finance and Admin CFO andMay 21Sale259.7466,83517,359,65258,554May 22 05:12 PM
GOLDBERG MURRAY ASVP Finance and Admin CFO andMay 20Option Exercise20.02147,9672,962,169135,803May 22 05:12 PM
BROWN MICHAEL SDirectorMay 17Sale269.025,0001,345,12014,662May 17 02:37 PM
BROWN MICHAEL SDirectorMay 15Option Exercise24.4115,000366,15029,662May 17 02:37 PM
BROWN MICHAEL SDirectorMay 15Sale278.2810,0002,782,80019,662May 17 02:37 PM
Aberman Michael SVP Strategy and Investor RelatMay 14Sale279.615,5291,545,96011,700May 15 05:04 PM
Aberman Michael SVP Strategy and Investor RelatMay 13Option Exercise24.0012,500300,00024,200May 15 05:04 PM
STAHL NEILSVP Research and Development SMay 13Sale276.8823,0386,378,80648,988May 14 11:51 AM
SING GEORGE LDirectorMay 10Option Exercise15.015,00075,050117,772May 10 04:19 PM
STAHL NEILSVP Research and Development SMay 10Option Exercise21.9255,4381,215,201104,426May 14 11:51 AM
SING GEORGE LDirectorMay 10Sale270.005,0001,350,000112,772May 10 04:19 PM
Terifay Robert JSVP CommercialMay 08Sale261.238,2312,150,19215,324May 09 04:59 PM
Terifay Robert JSVP CommercialMay 07Option Exercise16.8016,923284,30630,074May 09 04:59 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 07Sale261.6113,7253,590,63710,736May 08 05:51 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriMay 07Sale262.64100,00026,263,5811,106,395May 08 05:49 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriMay 06Option Exercise13.00192,3082,500,0041,309,638May 08 05:49 PM
Tessier-Lavigne MarcDirectorMay 06Option Exercise53.2313,334709,8348,334May 08 05:52 PM
SHOOTER ERIC MDirectorMay 06Option Exercise37.0920,000741,8005,039May 08 05:53 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 06Option Exercise16.8032,950553,56039,784May 08 05:51 PM
GILMAN ALFRED GDirectorMay 06Option Exercise21.7730,000652,9509,600May 08 05:54 PM
Aberman Michael SVP Strategy and Investor RelatMay 06Option Exercise24.008,334200,01618,434May 08 05:55 PM
GILMAN ALFRED GDirectorMay 06Sale261.0430,0007,831,3020May 08 05:54 PM
SHOOTER ERIC MDirectorMay 06Sale261.9610,0002,619,6482,500May 08 05:53 PM
SHOOTER ERIC MDirectorMay 06Sale259.3620,0005,187,2240May 08 05:53 PM
Tessier-Lavigne MarcDirectorMay 06Sale260.9113,3343,478,9420May 08 05:52 PM
Aberman Michael SVP Strategy and Investor RelatMay 06Sale257.138,3342,142,92711,700May 08 05:55 PM
VAGELOS P ROYChairman of the BoardMay 06Sale263.2113,4823,548,550114,018May 08 05:50 PM
McCorkle Douglas SVP Controller & Asst TreasurerMay 02Sale244.792,213541,7254,000May 03 04:09 PM
McCorkle Douglas SVP Controller & Asst TreasurerMay 01Option Exercise52.035,875305,6769,875May 03 04:09 PM
SCHLEIFER LEONARD SPresident & CEOMay 01Sale237.65100,00023,765,28942,087May 03 04:09 PM
McCorkle Douglas SVP Controller and Asst TreasurApr 12Sale211.013,129660,2354,000Apr 16 12:39 PM
McCorkle Douglas SVP Controller and Asst TreasurApr 11Option Exercise30.635,875179,9519,875Apr 16 12:39 PM
GOLDSTEIN JOSEPH LDirectorApr 01Option Exercise24.415,000122,0505,000Apr 02 09:23 AM
GOLDSTEIN JOSEPH LDirectorApr 01Sale180.005,000900,0000Apr 02 09:23 AM
BROWN MICHAEL SDirectorMar 21Option Exercise18.6115,000279,15021,422Mar 22 04:32 PM
BROWN MICHAEL SDirectorMar 21Sale173.2715,0002,599,02214,662Mar 22 04:32 PM
SCHLEIFER LEONARD SPresident & CEOMar 19Sale175.023,655639,698142,087Mar 21 04:18 PM
SCHLEIFER LEONARD SPresident & CEOMar 13Sale175.014,662815,897145,742Mar 15 05:03 PM
SCHLEIFER LEONARD SPresident & CEOMar 07Sale175.133,534618,909150,404Mar 07 05:08 PM
SCHLEIFER LEONARD SPresident & CEOMar 06Sale175.3869,00312,101,570153,938Mar 07 05:08 PM
SCHLEIFER LEONARD SPresident & CEOMar 05Sale175.2119,1463,354,571222,941Mar 07 05:08 PM
SHOOTER ERIC MDirectorFeb 26Sale160.0010,0001,600,0002,500Feb 28 02:32 PM
GOLDBERG MURRAY ASVP Finance and Admin CFO TreaJan 16Sale172.167,8781,356,27258,592Jan 17 04:30 PM
GOLDSTEIN JOSEPH LDirectorJan 09Option Exercise57.115,000285,5505,000Jan 09 05:13 PM
Powchik PeterSVP Clin Devel & Reg AffairsJan 09Option Exercise17.385,75299,98020,742Jan 10 09:25 AM
GOLDSTEIN JOSEPH LDirectorJan 09Sale185.005,000925,0000Jan 09 05:13 PM
GOLDSTEIN JOSEPH LDirectorJan 04Option Exercise33.425,000167,1002,740Jan 07 10:02 AM
GOLDSTEIN JOSEPH LDirectorJan 04Sale180.835,000904,1270Jan 07 10:02 AM
Powchik PeterSVP Clin Devel & Reg AffairsJan 03Sale182.1113,5862,474,09114,990Jan 04 10:00 AM
Powchik PeterSVP Clin Devel & Reg AffairsJan 02Option Exercise21.2530,000637,50044,990Jan 04 10:00 AM
Van Plew Daniel PSVP & Gen Mgr IOPSDec 20Option Exercise16.802,05034,4406,834Dec 21 03:17 PM
Powchik PeterSVP Clin Devel & Reg AffairsDec 20Sale170.646,6231,130,16414,990Dec 20 04:17 PM
YANCOPOULOS GEORGEEVP CSO Pres Regen Res LabsDec 19Option Exercise13.7750,846699,9781,117,330Dec 21 03:11 PM
McCorkle Douglas SVP Controller & Asst TreasurerDec 19Sale175.441,841322,9864,000Dec 20 04:16 PM
Powchik PeterSVP Clin Devel & Reg AffairsDec 19Sale178.5010,3561,848,53621,613Dec 20 04:17 PM
Aberman Michael SVP Strategy and Investor RelatDec 18Option Exercise24.001,20028,80011,700Dec 19 04:24 PM
Terifay Robert JSVP CommercialDec 18Option Exercise16.805,95299,99415,324Dec 19 04:23 PM
Powchik PeterSVP Clin Devel & Reg AffairsDec 18Option Exercise31.6138,2481,209,09039,446Dec 20 04:17 PM
McCorkle Douglas SVP Controller & Asst TreasurerDec 18Option Exercise21.254,62598,2817,873Dec 20 04:16 PM
McCorkle Douglas SVP Controller & Asst TreasurerDec 18Sale179.00752134,6065,841Dec 20 04:16 PM
STAHL NEILSVP Res and Devel SciencesDec 17Option Exercise16.805,95299,99448,988Dec 18 11:31 AM
McCorkle Douglas SVP Controller & Asst TreasurerDec 17Option Exercise16.805,00084,0004,800Dec 18 11:31 AM
YANCOPOULOS GEORGEEVP CSO Pres Regen Res LabsDec 17Option Exercise109.2910,3691,133,2281,304,811Dec 18 11:33 AM
GOLDBERG MURRAY ASVP Fin & Admin CFO Asst SecyDec 17Option Exercise20.321,85037,59266,470Dec 18 11:34 AM
McCorkle Douglas SVP Controller & Asst TreasurerDec 17Sale179.201,000179,1984,000Dec 18 11:31 AM
Aberman Michael SVP Strategy and Investor RelatDec 11Sale185.063,368623,26810,500Dec 12 09:34 AM
Aberman Michael SVP Strategy and Investor RelatDec 10Option Exercise30.637,500229,72518,000Dec 12 09:34 AM
STAHL NEILSVP Res and Devel SciencesNov 30Option Exercise21.099,483199,99451,422Dec 03 04:20 PM
ROBERTS WILLIAMVP Regulat Dev & Med SafetyNov 30Sale180.7811,5002,078,9750Dec 04 04:09 PM
STAHL NEILSVP Res and Devel SciencesNov 30Sale181.0117,1823,110,11441,939Dec 03 04:20 PM
Aberman Michael SVP Strategy and Investor RelatNov 30Sale180.643,904705,22810,500Dec 03 04:21 PM
Aberman Michael SVP Strategy and Investor RelatNov 29Option Exercise24.008,334200,01618,834Dec 03 04:21 PM
SING GEORGE LDirectorNov 29Sale185.005,000925,000122,772Nov 29 01:30 PM
VAGELOS P ROYChairman of the BoardNov 29Sale179.4778,63014,111,46856,946Nov 30 01:47 PM
VAGELOS P ROYChairman of the BoardNov 28Sale175.037,0041,225,910135,576Nov 30 01:47 PM
VAGELOS P ROYChairman of the BoardNov 27Sale175.3036,2466,353,788142,580Nov 27 06:23 PM
BAKER CHARLES ADirectorNov 26Option Exercise9.1715,000137,55016,155Nov 27 05:54 PM
BAKER CHARLES ADirectorNov 26Sale173.8715,0002,607,9869,590Nov 27 05:54 PM
VAGELOS P ROYChairman of the BoardNov 26Sale175.1228,5074,992,146178,826Nov 27 06:23 PM
VAGELOS P ROYChairman of the BoardNov 23Option Exercise19.43312,5006,071,875369,446Nov 27 06:23 PM
Terifay Robert JSVP CommercialNov 23Sale174.459,7451,699,9709,372Nov 26 03:39 PM
Terifay Robert JSVP CommercialNov 21Option Exercise16.8020,000336,00029,372Nov 26 03:39 PM
STAHL NEILSVP Res and Devel SciencesNov 21Sale174.3024,3574,245,44259,121Nov 21 03:50 PM
STAHL NEILSVP Res and Devel SciencesNov 20Option Exercise16.8054,500915,600104,219Nov 21 03:50 PM
VAGELOS P ROYChairman of the BoardNov 19Sale160.6132,5005,219,974127,500Nov 20 09:50 AM
SCHLEIFER LEONARD SPresident & CEONov 16Option Exercise111.0143,7574,857,465338,920Nov 19 05:25 PM
SING GEORGE LDirectorNov 16Sale152.005,000760,000127,772Nov 20 04:14 PM
Van Plew Daniel PSVP & General Mgr Industrial ONov 16Sale155.7018,7412,917,8994,784Nov 16 05:03 PM
BROWN MICHAEL SDirectorNov 14Option Exercise23.847,000166,88021,662Nov 15 10:26 AM
BROWN MICHAEL SDirectorNov 14Sale147.037,0001,029,21014,662Nov 15 10:26 AM
GOLDBERG MURRAY ASVP Finance and Admin CFO TreaNov 14Sale148.273,156467,95483,977Nov 15 05:12 PM
GOLDBERG MURRAY ASVP Finance and Admin CFO TreaNov 13Option Exercise41.738,176341,19595,357Nov 15 05:12 PM
SING GEORGE LDirectorNov 13Sale148.005,000740,000132,772Nov 15 05:13 PM
GOLDBERG MURRAY ASVP Finance and Admin CFO TreaNov 13Sale147.266,537962,63487,133Nov 15 05:12 PM
open in yahoo | open in reuters | open in google